Teladoc Health, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TDOC research report →
Range $7.5 – $11
Price Chart
About the company
Teladoc Health, Inc. offers remote medical services to individuals both domestically in the United States and internationally. Their extensive range of solutions covers a wide array of health needs, from routine and acute conditions to complex and long-term illnesses such as diabetes, hypertension, chronic kidney disease, cancer, congestive heart failure, and various mental health issues.
- CEO
- Charles Divita
- IPO
- 2015
- Employees
- 5,124
- HQ
- New York, NY, US
Get TickerSpark's AI analysis on TDOC
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.36B
- P/E
- -9.06
- Fwd P/E
- 48.06
- PEG
- -0.22
- P/S
- 0.58
- P/B
- 1.09
- EV/EBITDA
- 6.80
- Div Yield
- 0.00%
- Gross Margin
- 73.18%
- Op Margin
- -6.07%
- Net Margin
- -6.27%
- ROE
- -11.63%
- ROIC
- -6.18%
Latest fiscal year · YoY change
- Revenue
- $2.53B-1.5%
- Gross Profit
- $1.76B-3.3%
- Op Income
- $-262,955,000
- Net Income
- $-200,322,000+80.0%
- EPS
- $-1.14+80.6%
- OCF Growth
- +0.2%
- FCF Growth
- +0.9%
- 52W High
- $9.89
- 52W Low
- $4.40
- 50D MA
- $6.92
- 200D MA
- $6.67
- Beta
- 1.97
- RSI (14)
- 48
- Avg Volume
- 4.22M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Teladoc delivered a solid Q3 with revenue near the high end of guidance, EBITDA above plan, and accelerating BetterHelp insurance momentum, while keeping a cautious stance on cash-pay and 2027 transitions.· October 28, 2026
- Consolidated revenue was $605 million, down 3.4% year over year, while adjusted EBITDA rose 13.5% to $79 million and margin improved to 13.1%.
- Integrated care revenue was $398 million, up 2.3% year over year, and adjusted EBITDA margin reached 18.8%, well above guidance.
- BetterHelp revenue was $207 million, down 12.8% year over year, but insurance revenue hit $32 million and weekly insurance-covered sessions reached 27 thousand.
- Full-year 2026 guidance was raised for revenue and EBITDA, while free cash flow guidance was narrowed and 4Q BetterHelp reflects a bigger pullback in ad spend.
- Management highlighted Teladoc 1, hybrid care expansion, and capital structure actions around the 2027 convertible note maturity as key strategic priorities.
Consolidated revenue was $605 million, down 3.4% year over year, and adjusted EBITDA was $79 million, up 13.5% year over year. Adjusted EBITDA margin was 13.1%, up about 200 basis points from last year. Net loss per share was $0.15 versus a loss of $0.28 a year ago. Free cash flow was $70 million in the quarter and $85 million year to date, with cash and cash equivalents of $850 million, up $76 million sequentially, and net debt to trailing adjusted EBITDA at 0.5x. For 2026, management now expects revenue of $2.39 billion to $2.44 billion, adjusted EBITDA of $277 million to $303 million, free cash flow of $135 million to $165 million, stock-based compensation below $50 million, and net loss per share of ($0.95) to ($0.75). For Q4, consolidated revenue is expected at $569 million to $615 million and adjusted EBITDA at $74 million to $100 million. Integrated care 2026 revenue growth is now expected at 1.1% to 2.1%, with adjusted EBITDA margin of 16.0% to 16.6%; Q4 revenue is expected to be flat to up 3.8% year over year. BetterHelp 2026 revenue is now expected to decline 16.1% to 12.9% year over year, with insurance revenue of $99 million to $105 million and adjusted EBITDA margin of 2.7% to 4.3%; Q4 BetterHelp revenue is expected to decline 31.5% to 18.5%, with insurance revenue of $32 million to $38 million.
Chuck Divita framed the quarter as solid execution with progress against four priorities: stronger integrated care, global/hybrid care expansion, BetterHelp’s pivot toward insurance, and operational excellence. He said Teladoc 1 has moved from announcement to execution, with initial launch partners engaged and broader availability expected in 2027, and said client interest is centered on more comprehensive, outcome-oriented care. On BetterHelp, he emphasized that the business is being reshaped for durability, with insurance access expanding and cash-pay pressure still expected to persist.
Mike Grasher emphasized that the company beat on profitability while revenue landed near the high end of guidance. He cited $605 million in revenue, $79 million in adjusted EBITDA, 13.1% margin, $70 million of free cash flow, and a strong balance sheet with $850 million in cash and 0.5x net debt to trailing adjusted EBITDA. He also laid out 2026 guidance updates, including raised revenue and EBITDA, narrowed free cash flow guidance, and a clearer path for BetterHelp insurance growth to $99 million to $105 million this year, while noting a plan to address the $1 billion convertible note maturity in June 2027 through a two-step approach subject to market conditions.
Analysts focused heavily on BetterHelp’s insurance ramp, the decline in cash-pay, and how quickly therapist capacity and utilization can scale. Management said the quarter’s insurance momentum reflected better therapist credentialing and onboarding, a national footprint, and platform changes that should improve efficiency and reduce administrative burden; they also said the 27 thousand weekly insurance-covered sessions imply an annualized run rate of over $140 million. On Teladoc 1, management said it is already in pilot with initial partners, should influence the 2027 selling season, and may help retention and new-client growth, but they stressed that broader financial guidance for 2027 will come later.
The call showed improving execution across both segments, with integrated care margin expansion and BetterHelp insurance scaling faster than expected. Management sounded confident that Teladoc 1, hybrid care, and BetterHelp’s in-network shift can create more durable growth over time, and they pointed to solid liquidity and strong free cash flow as supporting flexibility.
The biggest risk remains BetterHelp’s cash-pay decline, which management expects to continue as the business lowers advertising and shifts toward insurance. Teladoc also warned that 2027 is still early and directional, with significant execution needed to scale therapist capacity, sustain insurance utilization, and manage the revenue tradeoff from reduced ad spend. In addition, the company faces a large June 2027 convertible note maturity and broader macro, regulatory, and healthcare-market uncertainty.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.3%
- Shares Outstanding
- 182.29M
- Float Shares
- 181.07M
of shares held by institutions
379 13F filers
Buy/sell ratio 0.50. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for TDOC, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Ro KhannaHouse · CA17 | Sell | Jun 26, 23 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Jan 11, 23 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Apr 11, 22 | Filing → |
| Donald Sternoff BeyerHouse · VA08 | Sell | Nov 26, 21 | Filing → |
| Donald Sternoff BeyerHouse · VA08 | Sell | Aug 18, 21 | Filing → |
| Donald Sternoff BeyerHouse · VA08 | Sell | Jun 21, 21 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Nov 19, 20 | Filing → |
| Donald Sternoff BeyerHouse · VA08 | Buy | Nov 17, 20 | Filing → |
| Greg GianforteHouse · MT00 | Sell | Oct 13, 20 | Filing → |
| Donald Sternoff BeyerHouse · VA08 | Sell | Jul 14, 20 | Filing → |
| Donald Sternoff BeyerHouse · VA08 | Sell | May 4, 20 | Filing → |
| Donald Sternoff BeyerHouse · VA08 | Sell | May 8, 20 | Filing → |
| Donald Sternoff BeyerHouse · VA08 | Sell | Apr 27, 20 | Filing → |
| Donald Sternoff BeyerHouse · VA08 | Sell | Apr 27, 20 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 21.48M | ▼ 427.24K |
| Blackrock, Inc. | 18.73M | ▲ 2.51M |
| Vanguard Portfolio Management LLC | 14.27M | ▲ 1.58M |
| American Century Companies Inc | 9.51M | ▲ 4.62M |
| Dimensional Fund Advisors LP | 9.10M | ▲ 1.73M |
| Point72 Asset Management, L.P. | 8.24M | ▲ 518.43K |
| Voss Capital, LP | 8.05M | ▲ 3.85M |
| Renaissance Technologies LLC | 8.00M | ▼ 70.00K |
| Vanguard Capital Management LLC | 7.98M | ▲ 25.75K |
| State Street Corp | 4.94M | ▼ 23.53K |
| Allianz Asset Management Gmbh | 4.67M | ▼ 124.77K |
| Geode Capital Management, LLC | 4.66M | ▲ 1.97K |
Held by 321 ETFs
Biggest fund positions in TDOC by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 6, 26 | Nueno Carlos | sell | 29,432 |
| Nov 2, 26 | Dorfman Jonathan | other | 0 |
| Nov 2, 26 | Dorfman Jonathan | other | 0 |
| Nov 2, 26 | Dorfman Jonathan | other | 0 |
| Nov 2, 26 | Dorfman Jonathan | other | 0 |
| Nov 2, 26 | Dorfman Jonathan | other | 0 |
| Nov 2, 26 | Dorfman Jonathan | other | 0 |
| Oct 1, 26 | Catapano Joseph Ronald | other | 2,083 |
| Oct 2, 26 | Catapano Joseph Ronald | sell | 655 |
| Oct 1, 26 | Catapano Joseph Ronald | other | 2,083 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our TDOC coverage
Recent articles, reports, and earnings notes.

What to Watch as SuperiorMed's SPAC Merger Heads to a Vote
SuperiorMed is a Dubai-based longevity, wellness, and medical tourism platform going public through a merger with STARRY SEA ACQUISITION CORP (Nasdaq: SSEA). The deal is still in the pre-close phase, with a shareholder meeting set for October 9, 2026 and the SPAC seeking more time to get the transaction done. The setup looks interesting on paper, but the real test is whether redemptions, dilution, and the lack of disclosed PIPE financing leave enough cash at closing.

Top Telehealth Stocks: Our 7 Picks for November 2026
A seven-stock countdown spans consumer telehealth, virtual-care platforms, physician enablement and chronic-care programs, with lower-ranked names including Teladoc, LifeMD and American Well.
Want a deeper read on TDOC?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Teladoc Health Expands Comprehensive Weight Care Program with Employer Contribution Option for GLP-1 Medications
globenewswire.com · Nov 17
Teladoc Health Canada Named Strategic Innovation Partner by NL Health Services to Advance Virtual Care Across the Province
businesswire.com · Nov 12
A $400 Billion Healthcare Opportunity: Telehealth Companies Positioned to Capitalize on a Massive Industry Shift
globenewswire.com · Nov 11
Teladoc Health Announces Employee Inducement Awards under NYSE Rule 303A.08
globenewswire.com · Nov 3
Teladoc Soars 26% as Revenue and Profit Beat Estimates; Hims & Hers Health and American Well Tick Up
247wallst.com · Oct 29
Teladoc Stock Rallies After Double Beat; Lifts FY26 GAAP EPS Outlook
benzinga.com · Oct 29
Teladoc Health, Inc. (TDOC) Q3 2026 Earnings Call Transcript
seekingalpha.com · Oct 29
Cathie Wood Is Buying Archer Aviation Stock. Here's What History Says About Following Ark Into a Stock Down 62%.
fool.com · Oct 29
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.